MIT’s Institute Prof. Robert Langer Presents A Boston Bio-Tech MUST Precision Targeted Medicine Curing Cancer

MIT’s Institute Prof. Robert Langer

Co-founder of Moderna Presents  

A Boston Bio-Tech MUST Precision Targeted Medicine 

MIT’s Tributeto Dr. Saul Hertz, Originator of the Medical Uses of RAI

Tuesday, Oct. 21… 2 p.m. – 4 p.m. 

Open to the Public -FREE- No Registration  

The Luria Auditorium, 500 Main Street Cambridge

Kendall/MIT subway station on the MBTA red line  

Robert Langer, ScD, MIT Institute Professor, Co-founder of Moderna: “Carrying the Legacy Forward” 

Ilya Gipp, MD, PhD – GE HealthCare, Chief Medical Officer-Oncology: “Beyond the Half Life: Linking a Discovery of the Past to the Future of Cancer Care” 

David Gilmore, EdD, President, 2007-2008, SNMMI-TS, Massachusetts College of Pharmacy & Health Sciences, Associate Professor, Nuclear Medicine: “Theranostics: Building a Critical Workforce” 

Annick D. Van den Abbeele, MD, FACR, FICIS, Professor of Radiology, Harvard Medical School, Dana-Farber Chair Emerita, Department of Imaging, Founding Director, Center for Biomedical Imaging in Oncology: “Theranostics: Characterizing the interplay between the TME co-conspirators for more effective therapy” 

Julie Price, PhD, MGH Department of Radiology, Director of PET Pharmacokinetic  Modeling, Martinos Center, Professor of Radiology, Harvard Medical School: “The  Importance of Nuclear Medicine Imaging in Aging and Neurodegeneration” 

Jason Dearling, PhD, Head of Radiopharmacology, Mariana Oncology/Novartis: “Targeting Radioligand Therapy for the treatment of Small Cell Lung Cancer (SCLC) and Beyond” 

Sheryl Mosessian, PhD, Chief Scientific Officer, SOFIE: “Probing Potential: How to Find Success Leveraging Academic-Biotech Partnerships” 

Alex Brown, MBA, CEO, Convergent Therapeutics: Moderator, Panel Discussion and Questions